ZHEJIANG WOLWO BIO-PHARMACEUTICAL CO., LTD.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

300357

CNE100001R58

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 08/05/2024 am IST			5-day change	1st Jan Change
26.29 ^CNY	+4.12%		+9.31%	-9.34%

18/04	Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2023	Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022

April 22, 2023 at 01:08 am IST

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. proposed final cash dividend of CNY 2.00000000 per ten shares (tax included) for 2022.

Latest news about Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	18/04	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/23/25	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/23/24	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 6, 2023	30/23/30	CI
Shanghai Wolwo Stem Cell Technology Co., Ltd. announced that it has received CNY 400 million in funding from Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	19/23/19	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022	20/23/20	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022	22/23/22	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	20/23/20	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Shanghai Wolwo Stem Cell Technology Co., Ltd. announced that it expects to receive CNY 400 million in funding from Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. and other investors	20/23/20	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Executive Appointments	30/22/30	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	20/22/20	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Implements Final Profit Distribution Plan A shares for 2021, Payable on June 16, 2022	11/22/11	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021	02/22/02	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2021	28/22/28	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/22/26	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/21/26	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	15/21/15	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 01 June 2021	27/21/27	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Final Cash Dividend for 2020	21/21/21	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2020	29/21/29	CI
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	27/21/27	CI
Stoxx Europe 600 : Chinese Shares End at Fresh Five-Year Highs; Pharma Stocks Post Double-Digit Gains	25/21/25	MT
Zhejiang Super Soul Artificial Intelligence Research Institute Co., Ltd. announced that it has received CNY 140 million in funding from Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	25/20/25	CI

Chart Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

More charts

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and sale of bio-pharmaceutical products. The Company's main products include Dermatophagoides Farinae Drops and Dermatophagoides Farinae Skin Prick Diagnostic Kits. The Company's products are primarily used for the treatment of allergic rhinitis caused by dust mite allergy, the desensitization of allergic asthma and the in-vivo diagnosis of dust mite drops. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

17/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.29 CNY

Average target price

27.96 CNY

Spread / Average Target

+6.33%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG WOLWO BIO-PHARMACEUTICAL CO., LTD.	-9.34%	1.9B
ELI LILLY AND COMPANY	+32.95%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.97%	358B
MERCK & CO., INC.	+18.83%	328B
ABBVIE INC.	+3.54%	283B
ASTRAZENECA PLC	+16.08%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+6.70%	165B

Other Pharmaceuticals